Biologic Activity of Digoxin-Specific Antisera

John F. Watson; Vincent P. Butler

doi:10.1172/JCI106853

^{Department of Medicine, School of Medicine, State University of New York at Buffalo, Buffalo, New York 14203}

^{Department of Medicine, Buffalo General Hospital, Buffalo, New York 14203}

^{Department of Medicine, Columbia University College of Physicians and Surgeons, New York 10032}

Find articles by Watson, J. in: PubMed | Google Scholar

^{Department of Medicine, School of Medicine, State University of New York at Buffalo, Buffalo, New York 14203}

^{Department of Medicine, Buffalo General Hospital, Buffalo, New York 14203}

^{Department of Medicine, Columbia University College of Physicians and Surgeons, New York 10032}

Find articles by Butler, V. in: PubMed | Google Scholar

Published in Volume 51, Issue 3 on March 1, 1972
J Clin Invest. 1972;51(3):638–648. https://doi.org/10.1172/JCI106853.
© 1972 The American Society for Clinical Investigation

Published March 1, 1972 - Version history

Digoxin-specific antibodies are capable of removing essentially all intracellular digoxin from rat renal cortical slices or from human erythrocytes. In removing digoxin from erythrocytes, these antibodies are capable of reversing an effect of the drug on cellular potassium transport. This study provides direct evidence that antibodies are capable of removing, and thereby reversing the biological effect of, physiologically active low molecular weight substances after they have been taken up by mammalian cells. This biologic property of digoxin-specific antibodies suggests that autidigoxin sera may prove useful in the reversal of digoxin toxicity.

Rapid and essentially quantitative removal of digoxin from red cells by antibody is not accompanied by an immediate restoration of patassium influx to normal levels. Identification of the mechanism of this phenomenon may provide useful information concerning the mode of action not only of digoxin, but also of the cation transport system of human erythrocytes.